Welt, Anja, Tewes, Mitra, Aktas, Bahriye, Wiesweg, Marcel, Ting, Saskia, Reis, Henning, Worm, Karl, Richly, Heike, Hense, Jörg, Peters, Malte, Schlegel, Robert, Lee, Benjamin, Palmer, Michael, Monahan, John, Scheulen, Max, Lehnerdt, Cathrin, Kohl, Marzena, Derks, Cordula, Skottky, Silke, Haus-Weiner, Ulrike, Schmid, Kurt, Kimmig, Rainer, Schuler, Martin and Kasper, Stefan (2013) Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients. Breast Cancer Research and Treatment, 142 (1). pp. 81-88. ISSN 0167-6806

Abstract

Biomarker-stratified cancer pharmacotherapy was pioneered in the care of breast cancer patients. The utility of agents modulating hormone receptors, synthesis of steroid hormones, or HER2-targeting agents has been greatly enhanced by the detection of predictive biomarkers in diagnostic tumor samples. Based on deeper understanding of breast cancer biology multiple drug candidates have been developed to modulate additional molecular targets which may associate with specific biomarker profiles. Accordingly, exploratory biomarkers are increasingly incorporated in early clinical trials, thus demanding a new process of patient selection. Here, we describe the implementation of preemptive, multiplexed biomarker profiling linked to standard diagnostic algorithms for metastatic breast cancer patients treated at the West German Cancer Center. Profiling for experimental biomarkers was prospectively offered to patients with metastatic breast cancer who met generic clinical trial inclusion criteria. Formalin-fixed, paraffin-embedded tumor samples were retrieved and studied for potentially "actionable" biomarkers related to active clinical trials by immunohistochemistry, amplicon sequencing, and in situ hybridization. The clinical course of those "profiled" patients was closely monitored to offer trial participation whenever applicable. Here, we report results from the first 131 patients enrolled in this program. PIK3CA mutations (23 %) and amplifications (2 %), loss of PTEN expression (13 %), and FGFR1 amplifications (8 %) were detected next to established biomarkers such as estrogen (67 %) and progesterone receptor expression (52 %), and HER2 overexpression or amplification (23 %). So far 16 "profiled" patients (12 %) have been enrolled in biomarker-stratified early clinical trials. Preemptive profiling of investigational biomarkers can be integrated into the diagnostic algorithm of a large Comprehensive Cancer Center. Extensive administrative efforts are required to successfully enroll "profiled" patients with metastatic breast cancer in early clinical trials stratified by exploratory biomarkers. © 2013 Springer Science+Business Media New York.

Item Type:	Article
Keywords:	Biomarker Metastatic breast cancer Mutation Personalized medicine Profiling
Date Deposited:	20 Dec 2017 00:45
Last Modified:	25 Jan 2019 00:46
URI:	https://oak.novartis.com/id/eprint/10311